,0
symbol,TCRR
price,26.9
beta,0.0
volAvg,279740
mktCap,899054460
lastDiv,0.0
range,5.84-27.17
changes,1.46
companyName,TCR2 Therapeutics Inc
currency,USD
cik,0001750019
isin,US87808K1060
cusip,87808K106
exchange,NasdaqGS
exchangeShortName,NASDAQ
industry,Biotechnology
website,http://www.tcr2.com/
description,"TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering t-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 71 full-time employees. The Companyâ€™s T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. The firm has demonstrated anti-tumor activity of TRuC-T cells in preclinical models across various tumor targets. The firm has also developed combinations of TRuC variants with elements designed to sustain the immunotherapeutic response and counteract the immunosuppressive tumor microenvironment. Its platform is highlighted with multiple programs of product candidate, which include TC-210, TC-220, TC-410, TC-110 and TC-310."
ceo,Dr. Garry Menzel
sector,Healthcare
country,US
fullTimeEmployees,87
phone,16179495200
address,100 Binney St
city,Cambridge
state,MASSACHUSETTS
zip,02142
dcfDiff,
dcf,22.094
image,https://financialmodelingprep.com/image-stock/TCRR.png
ipoDate,2019-02-14
defaultImage,False
